Seattle biotech can pursue $23M claim


Strict Standards: Declaration of C_DataMapper_Driver_Base::define() should be compatible with C_Component::define($context = false) in /nfs/c06/h01/mnt/156219/domains/ on line 0

That resulted in doctors billing Medicare for unapproved uses of the drug. After a CTI whistleblower sued on behalf of the government under what’s called a “qui tam” lawsuit, the company agreed to settle the case for $10.5 million without admitting liability. Whistleblowers in successful qui tam cases are entitled to a portion of the money recovered by the government.

CTI, believing the mistake was not its fault, sued Lash Group, hoping to recover the $10.5 million plus $12.3 million in attorneys fees and damages, including loss of reputation.

Historically, courts have not allowed defendants in qui tam lawsuits to try to recoup their fines or settlements by suing others — the principle being that they should not be able to avoid paying for their sins.

But here, the 9th Circuit panel held in an opinion by Judge M. Margaret McKeown that CTI settled without admitting liability — so it’s far from clear it engaged in any wrongdoing. Therefore, the court said, it should be allowed to pursue its claims against Lash. The panel sent the case back to U.S. District Court in Seattle.

Read the rest of the AP article here.



You can be the first one to leave a comment.


Leave a Comment


You must be logged in to post a comment.